Infection Risk for Patients With Myeloproliferative Neoplasms
Matched cohort study showed risk greatest for those with primary myelofibrosis, but still high for those with polycythemia vera and essential thrombocythemia.
Myeloproliferative Neoplasms
Evaluation of Real-World Experience With Long-Term Use of Anagrelide in the Setting of Essential Thrombocythemia
Anagrelide, a platelet-lowering agent with US FDA approval and EMA licensing for the treatment of patients with ET, is associated with prolonged response to initial therapy.
Low-Dose Aspirin Administered Twice-Daily Is Optimal for Thrombosis Reduction in Essential Thrombocythemia, Study Finds
Previous mostly retrospective/observational studies evaluated low-dose aspirin administered once daily in the setting of ET. In this study, the more frequent dosing was found optimal.
Management of Patients With Myelofibrosis Experiencing Ruxolitinib Failure
Identification of the underlying pattern for ruxolitinib failure in patients with myelofibrosis is a significant factor in determining appropriate treatment.
Persistent Leukocytosis as a Marker for Disease Progression in Polycythemia Vera
Although most notably associated with erythrocytosis, hematologic manifestations of polycythemia vera may also include leukocytosis and thrombocytosis.
Second Cancers Pose Significant Mortality Risk in Myeloproliferative Neoplasms
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
Increased Risk of Venous Thromboembolism in Patients With Myelofibrosis
One finding from this study was that VTE was more likely to occur at atypical sites in patients with myelofibrosis compared to those without the disease.
Splanchnic Vein Thrombosis at Presentation of Polycythemia Vera or Essential Thrombocythemia Associated With Increased Mortality
This study investigated differences in the morbidity and mortality of patients presenting with PV or ET with and without splanchnic vein thrombosis.
Ropeginterferon Alfa-2b as a New First-Line Therapy for Polycythemia Vera
In the extension study, 53% of patients receiving ropeginterferon alfa-2b met the primary end points, compared with 38% of patients receiving hydroxyurea.
Pregnancy in Myeloproliferative Neoplasms: Aspirin May Raise Likelihood of Live Birth
Researchers examined pregnancy outcomes in 102 patients with essential thrombocythemia.
-
Loading...
-
Loading...
Next post in General Hematology
